Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 72.4
(1.7%)
INR 72.4
(1.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -151.95 Million INR | 29.39% |
| 2022 | -219.39 Million INR | 44.45% |
| 2021 | -394.93 Million INR | -66.89% |
| 2020 | -236.65 Million INR | 1.79% |
| 2019 | -240.96 Million INR | -58.2% |
| 2018 | -152.31 Million INR | -19.8% |
| 2017 | -127.14 Million INR | 20.78% |
| 2016 | -160.49 Million INR | 1.66% |
| 2015 | -163.2 Million INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2011 | -193.39 Million INR | -95.54% |
| 2010 | -98.9 Million INR | 32.63% |
| 2009 | -146.8 Million INR | 66.28% |
| 2008 | -435.38 Million INR | -279.67% |
| 2007 | -114.67 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -38.86 Million INR | 18.78% |
| 2023 Q4 | -47.85 Million INR | -25.26% |
| 2023 FY | -154.9 Million INR | 29.39% |
| 2023 Q2 | -26.11 Million INR | 38.89% |
| 2023 Q1 | -42.73 Million INR | 30.0% |
| 2023 Q3 | -38.2 Million INR | -46.31% |
| 2022 Q3 | -46.79 Million INR | -30.19% |
| 2022 Q2 | -35.93 Million INR | 54.86% |
| 2022 Q1 | -79.61 Million INR | 32.68% |
| 2022 FY | -219.39 Million INR | 44.45% |
| 2022 Q4 | -61.04 Million INR | -30.46% |
| 2021 Q3 | -113.18 Million INR | -22.98% |
| 2021 Q2 | -92.04 Million INR | -15.9% |
| 2021 Q4 | -118.27 Million INR | -4.49% |
| 2021 FY | -394.93 Million INR | -66.89% |
| 2021 Q1 | -79.41 Million INR | -33.75% |
| 2020 Q3 | -68.31 Million INR | -60.15% |
| 2020 FY | -236.65 Million INR | 1.79% |
| 2020 Q4 | -59.37 Million INR | 13.09% |
| 2020 Q1 | -54.89 Million INR | -10.34% |
| 2020 Q2 | -42.65 Million INR | 22.29% |
| 2019 Q4 | -49.74 Million INR | 10.85% |
| 2019 FY | -240.96 Million INR | -58.2% |
| 2019 Q1 | -59.81 Million INR | -77.17% |
| 2019 Q2 | -62.16 Million INR | -3.93% |
| 2019 Q3 | -55.8 Million INR | 10.23% |
| 2018 Q2 | -16.16 Million INR | 57.91% |
| 2018 Q1 | -38.41 Million INR | 33.26% |
| 2018 FY | -152.31 Million INR | -19.8% |
| 2018 Q4 | -33.76 Million INR | 32.54% |
| 2018 Q3 | -50.04 Million INR | -209.58% |
| 2017 Q3 | 4.42 Million INR | 109.1% |
| 2017 Q1 | -59.33 Million INR | -62.36% |
| 2017 Q4 | -57.55 Million INR | -1400.99% |
| 2017 FY | -127.14 Million INR | 20.78% |
| 2017 Q2 | -48.6 Million INR | 18.09% |
| 2016 Q2 | -41.6 Million INR | -11.87% |
| 2016 FY | -160.49 Million INR | 1.66% |
| 2016 Q3 | -45.16 Million INR | -8.56% |
| 2016 Q1 | -37.18 Million INR | 38.13% |
| 2016 Q4 | -36.54 Million INR | 19.07% |
| 2015 Q1 | -29.51 Million INR | 0.0% |
| 2015 FY | -163.2 Million INR | 0.0% |
| 2015 Q2 | -40.76 Million INR | -38.12% |
| 2015 Q3 | -32.82 Million INR | 19.49% |
| 2015 Q4 | -60.1 Million INR | -83.13% |
| 2014 FY | - INR | 0.0% |
| 2014 Q3 | -14 Million INR | 0.0% |
| 2013 Q2 | -19.04 Million INR | 0.0% |
| 2013 Q3 | -21 Million INR | -10.32% |
| 2012 Q3 | -80.64 Million INR | -69.81% |
| 2012 Q2 | -47.49 Million INR | 0.0% |
| 2011 Q3 | -54.26 Million INR | 6.18% |
| 2011 FY | -193.39 Million INR | -95.54% |
| 2011 Q4 | -26.23 Million INR | 51.65% |
| 2011 Q2 | -57.83 Million INR | 0.0% |
| 2010 FY | -98.9 Million INR | 32.63% |
| 2009 FY | -146.8 Million INR | 66.28% |
| 2008 FY | -435.38 Million INR | -279.67% |
| 2008 Q4 | -141.15 Million INR | 0.0% |
| 2007 FY | -114.67 Million INR | 0.0% |
| 2007 Q4 | -36.29 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 102.639% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 100.36% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 101.692% |
| Granules India Limited | 6.81 Billion INR | 102.229% |
| Indoco Remedies Limited | 1.29 Billion INR | 111.756% |
| Achyut Healthcare Limited | 4.43 Million INR | 3523.997% |
| Ajanta Pharma Limited | 19.67 Billion INR | 100.772% |
| Alkem Laboratories Limited | 19.46 Billion INR | 100.781% |
| Alpa Laboratories Limited | 184.49 Million INR | 182.363% |
| Brooks Laboratories Limited | 14.44 Million INR | 1152.334% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 108.848% |
| Bajaj HealthCare Limited | - INR | Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 112.344% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 100.224% |
| Eris Lifesciences Limited | 5.18 Billion INR | 102.933% |
| FDC Limited | 2.98 Billion INR | 105.089% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 102.337% |
| Gufic Biosciences Limited | 1.32 Billion INR | 111.426% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 103.438% |
| Ipca Laboratories Limited | 7.98 Billion INR | 101.904% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 129.905% |
| Lasa Supergenerics Limited | -458 Million INR | 66.822% |
| Laurus Labs Limited | 3.94 Billion INR | 103.848% |
| Lupin Limited | 28.04 Billion INR | 100.542% |
| Mankind Pharma Limited | 21.51 Billion INR | 100.706% |
| Medicamen Biotech Limited | - INR | Infinity% |
| Medico Remedies Limited | 100.3 Million INR | 251.502% |
| Megasoft Limited | -121.1 Million INR | -25.476% |
| NATCO Pharma Limited | 25.96 Billion INR | 100.585% |
| Piramal Pharma Limited | 4.55 Billion INR | 103.335% |
| RPG Life Sciences Limited | 2.29 Billion INR | 106.629% |
| Sigachi Industries Limited | 1.47 Billion INR | 110.31% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 100.146% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 103.298% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 160.965% |
| Unichem Laboratories Limited | - INR | Infinity% |
| Wanbury Limited | 569.71 Million INR | 126.672% |
| Windlas Biotech Limited | 1.29 Billion INR | 111.699% |
| ZIM Laboratories Limited | 253.82 Million INR | 159.866% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 100.353% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 96.307% |
| Divi's Laboratories Limited | 33.08 Billion INR | 100.459% |
| Hester Biosciences Limited | 364.81 Million INR | 141.654% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 105.454% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 133.211% |
| Bal Pharma Limited | 233.9 Million INR | 164.964% |
| Strides Pharma Science Limited | 5.22 Billion INR | 102.908% |
| Venus Remedies Limited | 534.65 Million INR | 128.422% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 104.858% |
| Nectar Lifesciences Limited | 923.8 Million INR | 116.449% |
| Shilpa Medicare Limited | 1.36 Billion INR | 111.122% |
| Aarti Drugs Limited | 7.14 Billion INR | 102.126% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 109.516% |
| Suven Life Sciences Limited | -1.22 Billion INR | 87.604% |
| Ind-Swift Limited | 1.22 Billion INR | 112.395% |
| Valiant Laboratories Limited | - INR | Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 101.064% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 96.056% |
| Themis Medicare Limited | 392.58 Million INR | 138.706% |
| Hikal Limited | 32.11 Million INR | 573.239% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 100.6% |
| Sequent Scientific Limited | - INR | Infinity% |
| Novartis India Limited | 626.5 Million INR | 124.255% |
| Wockhardt Limited | -670 Million INR | 77.32% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 102.928% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | 1775.621% |
| Neuland Laboratories Limited | 5.31 Billion INR | 102.857% |
| Morepen Laboratories Limited | 4.17 Billion INR | 103.641% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 173.039% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | 653.416% |